Dolutegravir Based Regimens: Virology/Resistance
M184V and the GEMINI Studies
Andrew Zolopa, MD, VP, Head, North America Medical Affairs
M184V and the GEMINI Studies
Andrew Zolopa, MD, VP, Head, North America Medical Affairs
Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study
Mark Underwood, Clinical Virologist and Development Investigator
Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study
Mark Underwood, Clinical Virologist and Development Investigator
DTG/3TC: Confirmed Virologic Withdrawals in the GEMINI-1 and -2 Studies
Nneka Nwokolo, Senior Global Medical Director
DTG/3TC: Confirmed Virologic Withdrawals in the GEMINI-1 and -2 Studies
Nneka Nwokolo, Senior Global Medical Director
DTG/3TC: Barrier to Resistance
Jan van Lunzen, Head of Translational Medical Research
DTG/3TC: Barrier to Resistance
Jan van Lunzen, Head of Translational Medical Research
Are you a US healthcare provider?
This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.
If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
Connect with our Medical Experts
Find my ViiV MSL
Easily find the ViiV Medical Science Liaison (MSL) in your area.
Request a Scientific Discussion
Submit a request for additional information from a ViiV Medical Expert.
Talk to a Medical Expert
Connect now with a live ViiV Medical Expert.
Contact Us
Chat Live
Get immediate assistance from a ViiV Healthcare Professional.
Call 1-888-226-8434
Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)
Report an Adverse Event
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-332-1088 or www.fda.gov/medwatch